Welcome to our dedicated page for CG Oncology news (Ticker: CGON), a resource for investors and traders seeking the latest updates and insights on CG Oncology stock.
CG Oncology, Inc. reports developments as a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec for bladder cancer. Its updates center on non-muscle invasive bladder cancer, including high-risk BCG-unresponsive, BCG-exposed and intermediate-risk disease settings, and describe clinical studies such as PIVOT-006, BOND-003 and CORE-008.
Recurring company news also covers financial results, FDA-related regulatory planning, clinical data presentations, manufacturing and BLA preparation, investor conference participation and research initiatives tied to NMIBC. The company's disclosures connect its operating cash position and development spending to the advancement of its bladder-sparing immunotherapy program.
Summary not available.